United States of America based
Biovista delivers custom drug repositioning, drug de-risking and clinical hold solutions for the Biopharma Industry. Biovista also develops powerful platform technologies for Life science and Biotechnology companies. Biovista has an ongoing R&D program to develop new and improve existing products and services.
TechnologiesAI Companies (Drug Discovery)
Drug repositioning specialist Biovista Inc. has tapped Hewlett Packard Enterprise Co. (HPE) to add greater computing power to Project Prodigy, a personalized medicine platform that leverages artificial intelligence (AI) to help doctors identify novel drugs for hard-to-treat patients.This proprietary platform, called COSS™ (Clinical Outcomes Search Space), supports Biovista scientists in uncovering non-obvious correlations between drugs, molecular targets, pathways, adverse events and diseases and constructing evidence-based biological plausibility rationale on a systematic and highly predictable basis.
Biovista’s repositioned drug candidate BVA201 targeting Multiple Sclerosis (MS) is ready for Proof of Concept (PoC) studies in man.
No services posted yet